

Pharmacology for Nurses

Pharmacology for Nurses

A Pathophysiologic Approach

Michael Patrick Adams

Adjunct Professor of Anatomy and Physiology
Hillsborough Community College
Formerly Dean of Health Professions
Pasco-Hernando State College

Leland Norman Holland, Jr.

Professor
Hillsborough Community College
Polk State College

Carol Quam Urban

Associate Dean for Practice and Strategic Initiatives
Associate Professor
College of Health and Human Services
George Mason University

Executive Portfolio Manager: Pamela Fuller
Development Editor: Teri Zak
Portfolio Management Assistant: Taylor Scuglik
Vice President, Content Production and Digital Studio: Paul DeLuca
Managing Producer Health Science: Melissa Bashe
Content Producer: Michael Giacobbe
Vice President, Sales & Marketing: David Gesell
Vice President, Director of Marketing: Brad Parkins
Executive Field Marketing Manager: Christopher Barry
Field Marketing Manager: Brittany Hammond

Director, Digital Studio: Amy Peltier
Digital Producer: Jeff Henn
Full-Service Vendor: Pearson CSC
Full-Service Project Management: Pearson CSC, Dan Knott
Manufacturing Buyer: Maura Zaldivar-Garcia, LSC Communications, Inc.
Cover Designer: Pearson CSC
Text Printer/Bindery: LSC Communications, Inc.
Cover Printer: Phoenix Color

Credits and acknowledgments for content borrowed from other sources and reproduced, with permission, in this textbook appear on appropriate page within text except for the following:

Unit 1 opener, dimdimich/Fotolia
Unit 2 opener, Lighthunter/Shutterstock
Unit 3 opener, nerthuz/Fotolia
Unit 4 opener, nerthuz/Fotolia
Unit 5 opener, Sebastian Kaulitzki/Fotolia
Unit 6 opener, nerthuz/Fotolia
Unit 7 opener, nerthuz/Fotolia
Unit 8 opener, nerthuz/Fotolia
Unit 9 opener, dimdimich/Fotolia
Cover, Pearson Education
Drug icon used throughout, tassel78/123RF.

Copyright © 2020, 2017, 2014, 2011, and 2008 by Pearson Education, Inc., or its affiliates. 221 River Street, Hoboken, NJ 07030. All Rights Reserved. Printed in the United States of America. This publication is protected by copyright, and permission should be obtained from the publisher prior to any prohibited reproduction, storage in a retrieval system, or transmission in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise. For information regarding permissions, request forms and the appropriate contacts within the Pearson Education Global Rights & Permissions Department, please visit www.pearsoned.com/permissions/

Unless otherwise indicated herein, any third-party trademarks that may appear in this work are the property of their respective owners and any references to third-party trademarks, logos or other trade dress are for demonstrative or descriptive purposes only. Such references are not intended to imply any sponsorship, endorsement, authorization, or promotion of Pearson's products by the owners of such marks, or any relationship between the owner and Pearson Education, Inc. or its affiliates, authors, licensees, or distributors.

Notice: Care has been taken to confirm the accuracy of information presented in this book. The authors, editors, and the publisher, however, cannot accept any responsibility for errors or omissions or for consequences from application of the information in this book and make no warranty, express or implied, with respect to its contents.

The authors and publisher have exerted every effort to ensure that drug selections and dosages set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package inserts of all drugs for any change in indications of dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new or infrequently employed drug.

Library of Congress Cataloging-in-Publication Data

Names: Adams, Michael, 1951- , author. | Holland, Leland Norman, 1957- , author. | Urban, Carol Q. (Carol Quam), author.

Title: Pharmacology for nurses : a pathophysiologic approach / Michael Patrick Adams, Leland Norman Holland, Jr., Carol Quam Urban.

Description: Sixth edition. | Hoboken, N.J. : Pearson, [2020] | Includes bibliographical references and index.

Identifiers: LCCN 2019000512 | ISBN 9780135218334 | ISBN 0135218330

Subjects: | MESH: Drug Therapy | Pharmacological Phenomena | Pharmacology | Nurses Instruction

Classification: LCC RM301 | NLM WB 330 | DDC 615/.1--dc23 LC record available at <https://lcn.loc.gov/2019000512>

ISBN-10: 0-13-521833-0
ISBN-13: 978-0-13-521833-4

About the Authors



MICHAEL PATRICK ADAMS, PHD, is an accomplished educator, author, and national speaker. The National Institute for Staff and Organizational Development in Austin, Texas, named Dr. Adams a Master Teacher. He has published two other textbooks with Pearson Publishing: *Core Concepts in Pharmacology* and *Pharmacology: Connections to Nursing Practice*.

Dr. Adams obtained his master's degree in pharmacology from Michigan State University and his doctorate in education from the University of South Florida. Dr. Adams

LELAND NORMAN HOLLAND, JR., PHD (NORM), over 25 years ago, started out like many scientists, planning for a career in basic science research. He was quickly drawn to the field of teaching in higher medical education, where he has spent most of his career. Among the areas where he has been particularly effective are preparatory programs in nursing, medicine, dentistry, pharmacy, and allied health. Dr. Holland is both a professor and supporter in nursing education nationwide. He brings to the profession a depth of knowledge in biology, chemistry, and medically related

CAROL QUAM URBAN, PHD, RN, Associate Professor, is the Associate Dean for Practice and Strategic Initiatives in the College of Health and Human Services at George Mason University in Fairfax, Virginia. Teaching in the School of Nursing for over 25 years, and most recently in the position of Director of the School, she considers pharmacology to be a course that truly integrates nursing knowledge, skills, and

was on the faculty of Lansing Community College and St. Petersburg College, and served as Dean of Health Professions at Pasco-Hernando State College for 15 years. He is currently Adjunct Professor of Biological Sciences at Hillsborough Community College.

I dedicate this book to nursing educators, who contribute every day to making the world a better and more caring place.

—MPA

subjects, such as microbiology, biological chemistry, and pharmacology. Dr. Holland's doctoral degree is in medical pharmacology. He is very much dedicated to the success of students and their preparation for careers in health care. He continues to motivate students in the lifelong pursuit of learning.

To the greatest family in the world: Karen, Alexandria, Caleb, and Joshua.

—LNHII

interdisciplinary teamwork. She has co-authored the Pearson textbook *Pharmacology: Connections to Nursing Practice* with Dr. Adams.

To my daughter, Joy, an extraordinary pediatric hematology-oncology nurse, and in memory of my son, Keith, and husband, Michael.

—CQU

Thank You

Our heartfelt thanks go out to our colleagues from schools of nursing across the country who have given their time generously to help create this exciting new edition. These individuals helped us plan and shape our book and resources by reviewing chapters, art, design, and more. *Pharmacology for Nurses: A Pathophysiologic*

Approach, sixth edition, has reaped the benefit of your collective knowledge and experience as nurses and teachers, and we have improved the materials due to your efforts, suggestions, objections, endorsements, and inspiration. Among those who gave their time generously are the following:

Beatrice Adams, PharmD
Critical Care Clinical Pharmacist
Tampa General Hospital
Department of Pharmacy
Tampa, Florida

Shannon Allen, CRNA, MSNA
Professor
New Mexico Junior College
Hobbs, New Mexico

Candyce Antley, RN, MN
Instructor
Midlands Technical College
Columbia, South Carolina

Culeta Armstrong, MSN, RN
Clinical Assistant Professor
University of Memphis
Memphis, Tennessee

**Wanda Barlow, MSN, RN,
FNP-BC**
Instructor
Winston-Salem State University
Winston-Salem, North Carolina

**Sophia Beydoun, RN, BSN, MSN,
AA-AND**
Professor
Henry Ford Community College
Dearborn, Michigan

Staci Boruff, PhD, RN
Assistant Academic Dean of Health
Programs
Professor of Nursing
Walters State Community College
Morristown, Tennessee

Bridget Bradley, PharmD, BCPP
Assistant Professor
Pacific University
Hillsboro, Oregon

**Mary M. Bridgeman, PharmD,
BCPS, CGP**
Clinical Assistant Professor
Rutgers University
Piscataway, New Jersey

**Reamer L. Bushardt, PharmD,
P.A.-C**
Professor
Wake Forest Baptist Health
Winston-Salem, North Carolina

**Marcus W. Campbell, PharmD,
BC-ADM**
Assistant Professor Pharmacy Practice
Director, Center for Drug Information
& Research
LECOM School of Pharmacy
Bradenton, Florida

Rachel Choudhury, MSN, MS, RN, CNE
Associate Dean and Program Director,
ABSN
Musco School of Nursing and Health
Professions
Brandman University
Irvine, California

Darlene Clark, MS, RN
Senior Lecturer in Nursing
Pennsylvania State University
University Park, Pennsylvania

**Janice DiFalco, RN, MSN, CNS,
CMSRN, FAACVPR**
Professor
San Jacinto College
Pasadena, Texas

Deepali Dixit, PharmD, BCPS
Clinical Assistant Professor
Rutgers University
Piscataway, New Jersey

Rachael Durie, PharmD, BCPS
Cardiology Clinical Pharmacist
Assistant Professor of Clinical
Pharmacy
Rutgers University
Neptune, New Jersey

Deborah Dye, RN, MSN
Assistant Professor/Nursing
Department Chair
Ivy Tech Community College
Lafayette, Indiana

Jacqueline Frock, RN, MSN
Professor of Nursing
Oklahoma City Community College
Oklahoma City, Oklahoma

**Jasmine D. Gonzalvo, PharmD,
BCPS, BC-ADM, CDE**
Clinical Associate Professor
Purdue University
West Lafayette, Indiana

Adina C. Hirsch, PharmD, BCNSP
Assistant Professor of Pharmacy
Practice
Philadelphia College of Osteopathic
Medicine
Philadelphia, Pennsylvania

Linda Howe, PhD, RN, CNS, CNE
Associate Professor
University of Central Florida
Orlando, Florida

**Anne L. Hume, PharmD, FCCP,
BCPS**
Professor of Pharmacy
University of Rhode Island
Kingston, Rhode Island

Ragan Johnson, DNP, APRN-BC
Assistant Professor
University of Tennessee
Memphis, Tennessee

Vinh Kieu, PharmD
Assistant Professor
George Mason University
Fairfax, Virginia

Dorothy Lee, PhD, RN, ANP-BC
Associate Professor of Nursing
Saginaw Valley State University
University Center, Michigan

Toby Ann Nishikawa, MSN, RN
Assistant Professor
Weber State University
Ogden, Utah

Dr. Diana Rangaves, PharmD, RPh
Director, Pharmacy Technology
Program
Santa Rosa Junior College
Santa Rosa, California

**Timothy Reilly, PharmD, BCPS,
CGP, FASCP**
Clinical Assistant Professor
Rutgers University
Piscataway, New Jersey

**Janet Czermak Russell, MS, MA,
APN-BC**
Associate Professor
Essex County College
Newark, New Jersey

Pooja Shah, PharmD
Clinical Assistant Professor
Rutgers University
Piscataway, New Jersey

Samantha Smeltzer, RN
Professor of Nursing
Mount Aloysius College
Cresson, Pennsylvania

Rose Marie Smith, RN, MS, CNE
Division Dean of Nursing, Liberal
Arts, Social and Behavioral
Sciences
Redlands Community College
El Reno, Oklahoma

Dustin Spencer, DNP, NP-C, ENP-BC
Assistant Professor of Nursing
Saginaw Valley State University
University Center, Michigan

**Dr. Jacqueline Stewart, DNP, CEN,
CCRN**
Associate Professor of Nursing
Wilkes University
Wilkes-Barre, Pennsylvania

**Rebecca E. Sutter, DNP, APRN,
FNP-BC**
Associate Professor
George Mason University
Fairfax, Virginia

Suzanne Tang, MSN, APRN, FNP-BC
Instructor
Rio Hondo College
Whittier, California

Ryan Wargo, PharmD, BCACP
Assistant Professor of Pharmacy
Practice
Director of Admissions
LECOM School of Pharmacy
Bradenton, Florida

Timothy Voytilla, MSN, ARNP
Nursing Program Director
Keiser University
Tampa, Florida

Preface

When students are asked which subject in their nursing program is the most challenging, pharmacology always appears near the top of the list. The study of pharmacology demands that students apply knowledge from a wide variety of the natural and applied sciences. Successfully predicting drug action requires a thorough knowledge of anatomy, physiology, chemistry, and pathology as well as the social sciences of psychology and sociology. Lack of adequate pharmacology knowledge can result in immediate and direct harm to the patient; thus, the stakes in learning the subject are high.

Pharmacology cannot be made easy, but it can be made understandable when the proper connections are made to knowledge learned in these other disciplines. The vast majority of drugs in clinical practice are prescribed for specific diseases, yet many pharmacology textbooks fail to recognize the complex interrelationships between pharmacology and pathophysiology. When drugs are learned in isolation from their associated diseases or conditions, students have difficulty connecting pharmacotherapy to therapeutic goals and patient wellness. The pathophysiology focus of this textbook gives the student a clearer picture of the importance of pharmacology to disease and, ultimately, to patient care. The approach and rationale of this textbook focus on a holistic perspective to patient care which clearly shows the benefits and limitations of pharmacotherapy in curing or preventing illness. In addition to its pathophysiology focus, medication safety and interdisciplinary teamwork are consistently emphasized throughout the text. Although difficult and challenging, the study of pharmacology is truly a fascinating, lifelong journey.

New to This Edition

The sixth edition of *Pharmacology for Nurses: A Pathophysiologic Approach* has been thoroughly updated to reflect current pharmacotherapeutics and advances in understanding disease.

- **NEW!** Applying Research to Nursing Practice feature illustrates how current medical research is used to improve patient teaching. Books, journals, or websites may be cited, and the complete source information provided in the References section at the end of the chapter.

- **NEW!** Key terms are listed at the beginning of each chapter along with corresponding page numbers that indicate where their definitions may be found within the chapter.
- **UPDATED!** Check Your Understanding questions appear throughout the drug chapters to reinforce student knowledge.
- **EXPANDED!** Includes more than 40 new drugs, drug classes, indications, and therapies that have been approved since the last edition.
- **UPDATED!** Black Box Warnings issued by the FDA are included for all appropriate drug prototypes.
- **UPDATED!** Pharmacotherapy Illustrated diagrams help students visualize the connection between pharmacology and the patient.
- **UPDATED!** Nursing Practice Application charts have been revised to contain current applications to clinical practice with key lifespan, safety, collaboration, and diversity considerations noted.

Organization and Structure—A Body System and Disease Approach


Pharmacology for Nurses: A Pathophysiologic Approach is organized according to body systems (units) and diseases (chapters). Each chapter provides the complete information on the drug classifications used to treat the diseases. Specially designed numbered headings describe key concepts and cue students to each drug classification discussion.

The pathophysiologic approach clearly places the drugs in context with how they are used therapeutically. The student is able to locate easily all relevant anatomy, physiology, pathology, and pharmacology in the same chapter in which the drugs are discussed. This approach provides the student with a clear view of the connection among pharmacology, pathophysiology, and the nursing care learned in other clinical courses.

The vast number of drugs available in clinical practice is staggering. To facilitate learning, this text uses drug prototypes in which the most representative drugs in each classification are introduced in detail. Students are less intimidated when they can focus their learning on one representative drug in each class.

This text uses several strategies to connect pharmacology to nursing practice. Throughout the text the student will find interesting features, such as Complementary and Alternative Therapies, Treating the Diverse Patient, Community-Oriented Practice, and Lifespan Considerations, that clearly place the drugs in context with their clinical applications. Applying Research to Nursing Practice features illustrate how current medical research is used to improve patient teaching. Patient Safety illustrates potential pitfalls that can lead to medication errors. PharmFacts contain statistics and facts that are relevant to the chapter. Check Your Understanding features encourage students to apply what they have already read in the chapter.

Students learn better when supplied with accurate, attractive graphics and rich media resources. *Pharmacology for Nurses: A Pathophysiologic Approach* contains a generous number of figures, with an unequaled art program. Pharmacotherapy Illustrated features appear throughout the text, breaking down complex topics into easily understood formats. Animations of drug mechanisms show the student step-by-step how drugs act.



Prototype Drug | Valproic Acid (*Depakene, others*)

Therapeutic Class: Antiseizure drug **Pharmacologic Class:** Valproate

Actions and Uses

Valproic acid has become a preferred drug for treating many types of epilepsy. This medication has several trade names and formulations, which can cause confusion when studying it.

- Valproic acid (Depakene) is the standard form of the drug given PO.
- Valproate sodium (Depacon) is the sodium salt of valproic acid given PO or IV.
- Divalproex sodium (Depakote ER) is a sustained release combination of valproic acid and its sodium salt in a 1:1 mixture. It is given PO and is available in an enteric-coated form.

All three formulations of the drug form the chemical *valproate* after absorption or on entering the brain. The pharmacokinetics of each form varies, and doses are not interchangeable. In this text, the name *valproic acid* is used to describe all forms of the drug, unless specifically stated otherwise.

Valproic acid is administered as monotherapy or in combination with other AEDs to treat absence seizures and complex partial seizures. Depakote ER is also approved for the prevention of migraine headaches and mania associated with bipolar disorder. Off-label indications include severe behavioral disturbances, such as agitation due to dementia, Alzheimer's disease, or explosive temper in patients with ADHD; persistent hiccups; and status epilepticus refractory to IV diazepam.

Administration Alerts

- Valproic acid is a gastrointestinal (GI) irritant. Advise patients not to chew extended-release tablets because mouth soreness will occur.
- Do not mix valproic acid syrup with carbonated beverages because it will trigger immediate release of the drug, which causes severe mouth and throat irritation.
- Open capsules and sprinkle on soft foods if the patient cannot swallow them.
- Pregnancy category D.

PHARMACOKINETICS (PO CAPSULES)

Onset	Peak	Duration
2–4 days	1–4 h	6–24 h

Adverse Effects

Side effects include sedation, drowsiness, GI upset, and prolonged bleeding time. Other effects include visual disturbances, muscle weakness, tremor, psychomotor agitation, bone marrow suppression, weight gain, abdominal cramps, rash, alopecia, pruritus, photosensitivity, erythema multiforme, and fatal hepatotoxicity. **Black Box Warning:** May result in fatal hepatic failure, especially in children under the age of 2 years. Nonspecific symptoms often precede hepatotoxicity: weakness, facial edema, anorexia, and vomiting. Liver function tests should be performed prior to treatment and at specific intervals during the first 6 months of treatment. Valproic acid can produce life-threatening pancreatitis and teratogenic effects, including spina bifida.

Contraindications: Hypersensitivity may occur. This medication should not be administered to patients with liver disease, bleeding dysfunction, pancreatitis, and congenital metabolic disorders.

Interactions

Drug-Drug: Valproic acid interacts with many drugs. For example, aspirin, cimetidine, chlorpromazine, erythromycin, and felbamate may increase valproic acid toxicity. Concomitant warfarin, aspirin, or alcohol use can cause severe bleeding. Alcohol, benzodiazepines, and other CNS depressants potentiate CNS depressant action. Use of clonazepam concurrently with valproic acid may induce absence seizures. Valproic acid increases serum phenobarbital and phenytoin levels. Lamotrigine, phenytoin, and rifampin lower valproic acid levels.

Lab Tests: Unknown.

Herbal/Food: Unknown.

Complementary and Alternative Therapies

THE KETOGENIC DIET FOR EPILEPSY

The ketogenic diet is most often used when seizures cannot be controlled through pharmacotherapy or when there are unacceptable adverse effects to the medications. Before antiseizure drugs were developed, this diet was a primary treatment for epilepsy. Recent studies have examined the possibility that the ketogenic diet could provide benefit for patients with Alzheimer's, Parkinson's, and other neurodegenerative diseases (Rajagopal, Sangam, Singh, & Joginapally, 2016; Veyrat-Durebex et al., 2018). The exact mechanism behind the effectiveness of the diet is unknown and appears to include both direct effect from ketone body increases, and metabolic changes that occur, increasing GABA and inhibitory neurotransmitters (Rho, 2017).

has a ketogenic ratio of 3 or 4 g of fat to 1 g of protein and carbohydrate (Azevedo de Lima et al., 2017). Because of the high ratio of fat in the diet, complications such as hyperlipidemia and hepatotoxicity may occur, and patients on this diet need to be monitored long term to detect these adverse effects (Azevedo de Lima et al., 2017; Arslan et al., 2016).

Research suggests that the diet produces a high success rate compared to standard treatment, with better control of seizures. Improvement may be noted rapidly and the diet appears to be equally effective for every seizure type. The most frequently reported adverse effects include vomiting, fatigue, constipation, diarrhea, and hunger. Cost and the difficulty of following the diet long term may also limit

Treating the Diverse Patient: Sports-Related Concussions

There is increased awareness and concern about sports-related concussions at all ages. Concussions are a form of traumatic brain injury (TBI) and can range from mild to severe, with immediate and long-term consequences, including dementia and chronic traumatic encephalopathy (Thomas et al., 2018). Ban, Botros, Madden, and Batjer (2016) found a relatively low incidence of sports-related TBI, but an estimated 13% of pediatric and 14% of adult injuries were considered moderate to severe. While headaches, dizziness, and visual disturbances were common after a mild injury, seizures were more common with severe sports-related concussions, and symptoms may persist and become chronic (Choe et al., 2016; Merritt, Rabinowitz, & Arnett, 2015).

Early detection and intervention is a key strategy in the appropriate treatment of a concussion, but not all patients, particularly children, seek treatment. Bryan, Rowhani-Rahbar, Comstock, & Rivara (2016) found that as many as 52% of high school sports and recreation-related concussions were not reported to a health-care provider, and the authors recommend expanding research to include recreation-related injuries as a cause of TBI. For children, parents play a key role in identifying and managing these injuries. However, particularly among parents with low income, education is lacking (Lin et al., 2015). Because seizures and long-term complications may occur after a moderate to severe injury, education on prevention and early detection may help to decrease these consequences.

Community-Oriented Practice

PREPARING FOR DISASTERS: THE NURSE'S ROLE

When a disaster strikes, nurses and other healthcare providers may be expected to provide disaster relief, whether or not they have received training in this area. Normal healthcare infrastructure may be severely diminished or absent, and nurses will be relied on to provide care and information and to be able to improvise due to a lack of resources. Ruskie (2016) points out that during such a disaster people and nurses experience the loss of basic needs, such as electricity and water, and a lack of providers, supplies, equipment, and staff. As well, nurses find themselves tending to populations not usually encountered in their usual practice setting, such as the homeless or mentally ill. All of this can cause nurses to experience psychosocial, physical, and emotional distress in ways that could not be anticipated in disaster preparedness drills.

In reviewing the state of current preparedness, Adams, Karlin, Eisenman, Blakely, and Glick (2017) and Gowing, Walker, Elmer, and Cummings (2017) suggest that community-oriented, interprofessional team approaches will be needed, and they advocate for

preparedness and training that goes beyond the current hospital or healthcare-based training programs. Novel approaches to training include using interactive, gaming, or other virtual strategies; involving communities in awareness and training for personal preparedness; and providing training that involves healthcare teams with defined competencies.

Whether the cause is a natural disaster, such as a tornado, an earthquake, or a hurricane, or a disaster caused by accidental causes or terrorism, nurses may be called upon to work very long hours, use whatever supplies they have on hand, make decisions without the benefit of consulting with other healthcare providers, and use the full extent of their education to make decisions about care. Planning ahead, participating in disaster preparedness drills while also expecting reduced or absent resources, working with unfamiliar patient populations, and becoming the resource for a community may be expected of the nurse in a disaster. Expecting the unexpected, but being prepared, is a role that nurses are well trained to fulfill.

Lifespan Considerations

Nonmedical Use of CNS Stimulant Medications

Whether due to improved diagnostic criteria or a true increase, the number of children in the United States diagnosed with ADHD continues to increase (Centers for Disease Control, 2018). As CNS stimulant prescriptions are used to treat the condition, the potential for misuse of the drugs rises. Multiple studies have investigated the nonmedical use of CNS stimulant medications (i.e., the misuse and diversion of the drugs for purposes other than the prescribed condition), and commonalities have emerged.

For children and adolescents, it appears that the earlier a stimulant drug is started, the less the chance for nonmedical use later, suggesting that there is a crucial time in brain and physical development that may increase the risk of misuse when the drugs are started in late childhood or adolescence (McCabe, Veliz, & Boyd, 2016). Among adolescents who used ADHD stimulants inappropriately, it was found that there was often a concurrent substance misuse problem, with alcohol being the most common substance also used (Chen, Crum, Strain, Martins, & Mojtabei, 2015;

McCabe, Veliz, & Patrick, 2017). Overall, a slight decrease in the use of amphetamine misuse declined in recent years in adolescents (Johnston et al., 2015), but no decline was noted in adults age 21 to 55 (Schulenberg et al., 2017). Physician prescribing practices also play a role. Colaneri, Keim, and Adesman (2017) found that few physicians used medication contracts or distributed drug education literature to their patients.

Being aware of high-risk populations can assist nurses with targeting interventions. "SBIRT" is an evidence-based model to identify and begin treatment for substance misuse (SAMHSA-HRSA Center for Integrated Health Solutions, n.d.). Using the model, **S**creening, **B**rief **I**ntervention, and **R**eferral to Treatment begins the process of treatment for substance misuse. Because nurses are often the first healthcare professional the patient encounters, and the one who provides the most health teaching, using the SBIRT model and a thorough drug and social history may aid in determining the patients most in need of additional treatment.

Applying Research to Nursing Practice: New Uses for Ketamine

Ketamine is classified as a general anesthetic that is used for conscious sedation, where a patient is conscious but dissociated from their environment with resultant amnesia. With the concern for opioid misuse, research into additional uses for ketamine is ongoing.

Past studies have demonstrated that ketamine has some effectiveness in treating depression in patients with bipolar disorder and depression in patients with a family history of alcohol use disorder (Niciu et al., 2014; Zarate et al., 2012). More recent studies have shown that ketamine may be useful in the treatment of post-traumatic stress disorder (PTSD), for treatment-resistant depression, and as a treatment for pain (Buvanendran et al., 2018; Hartberg, Garrett-Walcott, & De Gioannis, 2018; Krystal et al., 2017; Schoevers, Chaves, Balukova, Rot, & Kortekaas, 2016). As concern grows over the misuse of opioids,

previous studies into the use of nonopioid treatments are being reconsidered.

Ketamine is usually given parenterally, but oral use has also been shown to be effective (Buvanendran et al., 2018; Hartberg, Garrett-Walcott, & De Gioannis, 2018; Schoevers et al., 2016). Specialized treatment centers are also being established touting the use of ketamine for depression, PTSD, obsessive-compulsive disorder, and fibromyalgia, even though published research accounts are in the preliminary stages. The authors acknowledge the need for more research and randomized clinical trials before the drug can be recommended for these disorders. Because patients may inquire about these treatment centers, nurses should know that ketamine is not currently approved for use in these conditions and advise patients to discuss any adjunctive treatment with their healthcare provider.

Patient Safety: Inappropriate Drug Substitution

A patient has Tylenol #3 with codeine ordered. When opening the medication dispensing system, the cassette for Tylenol #3 is empty, but Tylenol #2 is available. Consulting a drug guide as needed, why

would it be inappropriate for the nurse to give two Tylenol #2 tablets in place of one Tylenol #3? See Appendix A for the answer.

PharmFacts

ANXIETY DISORDERS

- An estimated 40 million American adults suffer from anxiety disorders.
- Illnesses that commonly coexist with anxiety include depression, eating disorders, and substance abuse.
- Anxiety disorders affect 25% of children between the ages of 13 and 18.
- Although highly treatable, only about 37% of those having an anxiety disorder receive treatment. (Anxiety and Depression Association of America, n.d.)

Source: Anxiety and Depression Association of America. (n.d.). Facts and statistics. Retrieved from <https://www.adaa.org/about-adaa/press-room/facts-statistics>

One of the strongest components of *Pharmacology for Nurses: A Pathophysiologic Approach* is the Nursing Practice Application feature. This feature clearly and concisely relates pharmacotherapy to patient assessment, planning patient outcomes, implementing patient-centered care, and evaluating the outcomes. Student feedback has shown that these Nursing Process Application charts are a significant component of planning and implementing nursing care plans.

The QSEN competencies related to patient-centered care, teamwork and collaboration, evidence-based practice, and patient safety are incorporated throughout the features and Nursing Practice Application charts.


No pharmacology text is complete unless it contains a method of self-assessment by which students may gauge their progress. *Pharmacology for Nurses: A Pathophysiologic Approach* contains an end-of-chapter review of the major concepts. NCLEX-RN®-style questions, a Patient-Focused Case Study with critical thinking questions, and an additional set of Critical Thinking questions allow students to check their retention of chapter material. References and Selected Bibliography sources are also located at the end of each chapter.

Check Your Understanding 13.1

A 64-year-old man is taking atenolol (Tenormin) for treatment of hypertension. His seasonal allergies have been worse this year, and he is considering an OTC decongestant, pseudoephedrine (Sudafed), which a friend recommended. Is this medication safe for him to take? See Appendix A for the answer.

Pharmacotherapy Illustrated

26.1 | Mechanism of Action of Antihypertensive Drugs



Nursing Practice Application

Pharmacotherapy with Adrenergic Drugs

ASSESSMENT

Baseline assessment prior to administration:

- Obtain a complete health history and drug history, including allergies, current prescription and over-the-counter (OTC) drugs, and herbal preparations. Be alert to possible drug interactions.
- Evaluate appropriate laboratory findings, such as liver or kidney function studies.
- Obtain baseline vital signs, weight, and urinary and cardiac output as appropriate.
- Assess the nasal mucosa for excoriation or bleeding prior to beginning therapy for nasal congestion.
- Assess the patient's ability to receive and understand instruction. Include the family and caregivers as needed.

Assessment throughout administration:

- Assess for desired therapeutic effects (e.g., increased ease of breathing, blood pressure (BP) within normal range, nasal congestion improved).
- Continue frequent and careful monitoring of vital signs and urinary and cardiac output as appropriate, especially if IV administration is used.
- Assess for and promptly report adverse effects: tachycardia, hypertension, dysrhythmias, tremors, dizziness, headache, and decreased urinary output. Immediately report severe hypertension, seizures, and angina, which may signal drug toxicity.

IMPLEMENTATION

Interventions and (Rationales)	Patient-Centered Care
<p>Ensuring therapeutic effects:</p> <ul style="list-style-type: none"> • Continue frequent assessments for therapeutic effects. (Pulse, BP, and respiratory rate should be within normal limits or within the parameters set by the healthcare provider. Nasal congestion should be decreased; reddened, irritated sclera should be improved.) • Provide supportive nursing measures; e.g., proper positioning for dyspnea, shock. (Supportive nursing measures will supplement therapeutic drug effects and optimize the outcome.) 	<ul style="list-style-type: none"> • Teach the patient or caregiver how to monitor the pulse and BP, as appropriate. Ensure the proper use and functioning of any home equipment obtained. • Teach the patient to report increasing dyspnea despite medication therapy and to not take more than the prescribed dose unless instructed otherwise by the healthcare provider.
<p>Minimizing adverse effects:</p> <ul style="list-style-type: none"> • Monitor for signs of excessive autonomic nervous system stimulation and notify the healthcare provider if the BP or pulse exceeds established parameters. Continue frequent cardiac monitoring (e.g., electrocardiogram [ECG], cardiac output) and urine output if IV adrenergics are given. (Adrenergic drugs stimulate the heart rate and raise BP, and require frequent monitoring. Lifespan: The older adult may be at greater risk due to previously existing cardiovascular disease. Diverse Patients: Research suggests African Americans may experience an impaired [diminished] vascular response to isoproterenol, and vital signs should be monitored frequently during administration.) • Closely monitor the IV infusion site when using IV adrenergics. All IV adrenergic drips should be given via infusion pump. (Blanching at the IV site is an indicator of extravasation and the IV infusion should be immediately stopped and the provider contacted for further treatment orders. Infusion pumps allow precise dosing of the medication.) • Continue to monitor blood glucose and appropriate laboratory work. (Adrenergic stimulation may increase blood glucose.) • Monitor oral and nasal mucosa and breath sounds in patients taking inhaled adrenergic drugs. (Inhaled epinephrine and other adrenergic drugs may reduce bronchial secretions, making removal of mucus more difficult.) • Inspect nasal mucosa for irritation, rhinorrhea, or bleeding after nasal use. Avoid prolonged use of adrenergic nasal sprays. (Vasoconstriction may cause transient stinging, excessive dryness, or bleeding. Rebound congestion with chronic rhinorrhea may result after prolonged treatment.) • Provide for eye comfort such as darkened room, soft cloth over eyes, and sunglasses. Transient stinging after installation of eyedrops may occur. (Mydriasis and photosensitivity to light may occur. Localized vasoconstriction may cause stinging of the eyes.) 	<ul style="list-style-type: none"> • Instruct the patient to report palpitations, shortness of breath, chest pain, excessive nervousness or tremors, headache, or urinary retention immediately. • Teach the patient to limit or eliminate the use of foods and beverages that contain caffeine because these may cause excessive nervousness, insomnia, and tremors. • To allay possible anxiety, teach the patient about the rationale for all equipment used and the need for frequent monitoring. • Teach the patient with diabetes to monitor his or her blood glucose more frequently and to notify the healthcare provider if a consistent increase is noted. A change in antidiabetes medications or dosing may be required if glucose remains elevated. • Teach the patient to increase fluid intake to moisten airways and assist in the expectoration of mucus, unless contraindicated. • Instruct the patient not to use nasal spray longer than 3–5 days without consulting the provider. OTC saline nasal sprays may provide comfort if mucosa is dry and irritated. Increasing oral fluid intake may also help with hydration. • Lifespan: Teach the caregiver that adrenergic nasal sprays and other decongestants are not recommended in children and should be used only under a provider's supervision. • Instruct the patient that photosensitivity may occur and sunglasses may be needed in bright light or for outside activities. The provider should be notified if irritation or sensitivity occurs beyond 12 hours after the drug has been discontinued. Soft contact lens users should check with the provider before using, as some solutions may stain lenses. Lifespan & Safety: Assist the older adult with ambulation if blurred vision or light sensitivity occurs, to prevent falls.
<p>Patient understanding of drug therapy:</p> <ul style="list-style-type: none"> • Use opportunities during administration of medications and during assessments to provide patient education. (Using time during nursing care helps to optimize and reinforce key teaching areas.) 	<ul style="list-style-type: none"> • The patient or caregiver should be able to state the reason for the drug; dose and scheduling; adverse effects to observe for and when to report; equipment needed as appropriate and how to use that equipment; and the required length of medication therapy needed with any special instructions regarding renewing or continuing the prescription as appropriate.
<p>Patient self-administration of drug therapy:</p> <ul style="list-style-type: none"> • When administering medications, instruct the patient or caregiver in proper self-administration of an inhaler, epinephrine injection kit, nasal spray, or ophthalmic drops. (Using time during nurse administration of these drugs helps to reinforce teaching.) 	<ul style="list-style-type: none"> • Instruct the patient in proper administration techniques, followed by teach-back. Inhalation forms should only be dispensed when the patient is upright to properly aerosolize the drug and prevent overdosage from excessively large droplets. • Teach the patient or caregiver proper technique for epinephrine auto-injector and to have on hand for emergency use at all times. If epinephrine auto-injector is needed and used, 911 and the healthcare provider should be called immediately after use. • Teach the patient or caregiver to not share nasal sprays with other people to prevent infection. • The patient or caregiver is able to discuss appropriate dosing and administration needs.

See Table 13.3 for a list of drugs to which these nursing actions apply.

Chapter Review

KEY Concepts

The numbered key concepts provide a succinct summary of the important points from the corresponding numbered section within the chapter. If any of these points are not clear, refer to the numbered section within the chapter for review.

13.1 Norepinephrine is the primary neurotransmitter released at adrenergic receptors, which are divided into alpha and beta subtypes. Drugs can affect nervous transmission across a synapse by preventing the synthesis, storage, or release of the neurotransmitter; by preventing the destruction of the neurotransmitter;

or by influencing the binding of neurotransmitters to the receptors.

13.2 Sympathomimetics act directly by activating adrenergic receptors or indirectly by increasing the release of norepinephrine from nerve terminals. They are used primarily for their effects on the heart (hypertension, cardiac arrest), bronchial tree (asthma, COPD), and nasal passages (nasal congestion).

13.3 Adrenergic-blocking drugs are used primarily for treatment of hypertension (minor use for BPH) and are the most widely prescribed class of autonomic drugs.

REVIEW Questions

- Following administration of phenylephrine (Neo-Synephrine), the nurse would assess for which adverse drug effects?
 - Insomnia, nervousness, and hypertension
 - Nausea, vomiting, and hypotension
 - Dry mouth, drowsiness, and dyspnea
 - Increased bronchial secretions, hypotension, and bradycardia
- Propranolol (Inderal) has been ordered for a patient with hypertension. Because of adverse effects related to this drug, the nurse would carefully monitor for which adverse effect?
 - Bronchodilation
 - Tachycardia
 - Edema
 - Bradycardia
- The healthcare provider prescribes epinephrine (Adrenalin) for a patient who was stung by several wasps 30 minutes ago and is experiencing an allergic reaction. The nurse knows that the primary purpose of this medication for this patient is to:
 - Stop the systemic release of histamine produced by the mast cells.
 - Counteract the formation of antibodies in response to an invading antigen.
 - Increase the number of white blood cells produced to fight the primary invader.
 - Increase a declining blood pressure and dilate constricting bronchi associated with anaphylaxis.
- A patient is started on atenolol (Tenormin). Which is the most important action to be included in the plan of care for this patient related to this medication?
 - Monitor apical pulse and blood pressure.
 - Elevate the head of the bed during meals.
 - Take the medication after meals.
 - Consume foods high in potassium.
- To avoid the first-dose phenomenon, the nurse knows that the initial dose of prazosin (Minipress) should be:
 - Very low and given at bedtime.
 - Doubled and given before breakfast.
 - The usual dose and given before breakfast.
 - The usual dose and given immediately after breakfast.
- A patient who is taking an adrenergic-blocker for hypertension reports being dizzy when first getting out of bed in the morning. The nurse should advise the patient to:
 - Move slowly from the recumbent to the upright position.
 - Drink a full glass of water before rising to increase vascular circulatory volume.
 - Avoid sleeping in a prone position.
 - Stop taking the medication.

PATIENT-FOCUSED Case Study

Tyrone Mathey is a 48-year-old man who is an attorney at a large law firm. He has made an appointment with his healthcare provider today for increased feelings of anxiety, headaches, and "just not feeling well." His medical and family histories indicate that both of his parents died within the last 10 years. His father died of a stroke and his mother died of a heart attack. Mr. Mathey states that he has been prescribed prazosin (Minipress) in the past but he stopped taking it. When questioned about why he chose not to take the medication, he reluctantly confides in you that he suspected the medication was causing adverse sexual effects.

His body temperature is 37°C (98.6°F), heart rate is 88 beats/min, respiratory rate is 18 breaths/min, and blood pressure is 160/90 mmHg. During the examination, an ECG and laboratory test results were all within normal limits.

- Identify the mechanism of action associated with prazosin (Minipress).
- Could the prazosin (Minipress) be the cause of his sexual adverse effects?
- As this patient's nurse, how would you approach the topic of medication-induced sexual dysfunction?

CRITICAL THINKING Questions

- A 24-year-old patient is evaluated for seasonal allergies by his healthcare provider. The provider recommends phenylephrine (Neo-Synephrine) nasal spray to treat symptoms related to allergic rhinitis. When teaching this patient about his medication, what therapeutic effects will the phenylephrine (Neo-Synephrine) provide? What adverse effects should the patient be observant for?
- A 66-year-old man has had increasing trouble with urination, including difficulty starting to urinate and feeling that his bladder has not completely emptied. His provider prescribes doxazosin (Cardura) for treatment of BPH. The patient is alarmed and asks the nurse, "Why was I prescribed this? My brother takes it for high blood pressure and my blood pressure is normal!" As the nurse, how would you respond?

See Appendix A for answers and rationales for all activities.

REFERENCES

- Chooniedass, R., Temple, B., & Becker, A. (2017). Epinephrine use for anaphylaxis: Too seldom, too late. *Annals of Allergy, Asthma & Immunology*, 119, 108–110. doi:10.1016/j.anaai.2017.06.004
- Shaker, M., Bean, K., & Verdi, M. (2017). Economic evaluation of epinephrine auto-injectors for peanut allergy. *Annals of Allergy, Asthma & Immunology*, 119, 160–163. doi:10.1016/j.anaai.2017.05.020

SELECTED BIBLIOGRAPHY

- Blaggioni, I., & Robertson, D. (2015). Adrenoceptor agonists & sympathomimetic drugs. In B. G. Katzung, S. B. Masters, & A. J. Trevor (Eds.), *Basic and clinical pharmacology* (13th ed., pp. 152–168). New York, NY: McGraw-Hill.
- Westfall, T. C., Macarthur, H., & Westfall, D. P. (2018). Adrenergic agonists and antagonists. In L. L. Brunton, R. Hilal-Dandan, & B. C. Knollmann (Eds.), *Goodman and Gilman's the pharmacological basis of therapeutics* (13th ed., 191–224). New York, NY: McGraw-Hill.
- Wysong, C. S., Bradley, H. A., Volmink, J., Mayosi, B. M., & Opi, L. H. (2017). Beta-blockers for hypertension. *Cochrane Database of Systematic Reviews*, 1, Art. No.: CD002003. doi:10.1002/14651858.CD002003.pub5

Acknowledgments

When authoring a textbook like this, many dedicated and talented professionals are needed to bring the vision to reality. Pamela Fuller, Executive Portfolio Manager, and Michael Giacobbe, Program Manager, are responsible for guiding the many details in the development and production of the sixth edition. Our Development Editor, Teri Zak, provided leadership, motivation, and expert guidance to keep everyone on track and on schedule. Her steadfast attention to detail

and her editorial expertise enabled an excellent outcome for this edition.

Although difficult and challenging, the study of pharmacology is truly a fascinating lifelong journey. We hope we have succeeded in writing a textbook that makes that study easier and more understandable so that nursing students will be able to provide safe, effective nursing care to patients who are undergoing drug therapy. We hope students and faculty will share with us their experiences using this textbook and all its resources.

Contents

About the Authors v
Thank You vi
Preface viii

Unit 1

Core Concepts in Pharmacology 1

1 Introduction to Pharmacology 2

- 1.1 History of Pharmacology 3
- 1.2 Pharmacology: The Study of Medicines 3
- 1.3 Pharmacology and Therapeutics 4
- 1.4 Classification of Therapeutic Agents as Drugs, Biologics, Biosimilars, and Complementary and Alternative Medicine Therapies 4
- 1.5 Therapeutic and Pharmacologic Classification of Drugs 4
- 1.6 Chemical, Generic, and Trade Names for Drugs 5
- 1.7 Prescription and Over-the-Counter Drugs 6
- 1.8 Differences Between Trade-Name Drugs and Their Generic Equivalents 6
- 1.9 Decisions Relative to Proper Drug Choices 8

2 Drug Approval and Regulation 10

- 2.1 Drug Regulations and Standards 11
- 2.2 The Role of the Food and Drug Administration 12
- 2.3 Phases of Approval for Therapeutic and Biologic Drugs 13
- 2.4 Changes to the Drug Approval Process 15
- 2.5 Prescriptive Authority for Nurses 15
- 2.6 Controlled Substances, Drug Schedules, and Teratogenic Risks 16

3 Principles of Drug Administration 19

- 3.1 Medication Knowledge and Understanding 20
- 3.2 The Rights of Drug Administration 21
- 3.3 Patient Adherence and Successful Pharmacotherapy 21
- 3.4 Drug Orders and Time Schedules 22
- 3.5 Systems of Measurement 23
- 3.6 Enteral Drug Administration 24
 - TABLETS AND CAPSULES 24
 - SUBLINGUAL AND BUCCAL DRUG ADMINISTRATION 25
 - RAPID-DISSOLVING TABLETS AND FILMS 26
 - NASOGASTRIC AND GASTROSTOMY DRUG ADMINISTRATION 26

- 3.7 Topical Drug Administration 26
 - TRANSDERMAL DELIVERY SYSTEM 27
 - OPHTHALMIC ADMINISTRATION 27
 - OTIC ADMINISTRATION 27
 - NASAL ADMINISTRATION 27
 - VAGINAL ADMINISTRATION 29
 - RECTAL ADMINISTRATION 30

- 3.8 Parenteral Drug Administration 30
 - INTRADERMAL AND SUBCUTANEOUS ADMINISTRATION 30
 - INTRAMUSCULAR ADMINISTRATION 31
 - INTRAVENOUS ADMINISTRATION 33

4 Pharmacokinetics 37

- 4.1 Pharmacokinetics: How the Body Handles Medications 38
- 4.2 The Passage of Drugs Through Plasma Membranes 38
- 4.3 Absorption of Medications 38
- 4.4 Distribution of Medications 40
- 4.5 Metabolism of Medications 41
- 4.6 Excretion of Medications 42
- 4.7 Drug Plasma Concentration and Therapeutic Response 43
- 4.8 Onset, Peak Levels, and Duration of Drug Action 45
- 4.9 Loading Doses and Maintenance Doses 45

5 Pharmacodynamics 48

- 5.1 Pharmacodynamics and Interpatient Variability 49
- 5.2 Therapeutic Index and Drug Safety 49
- 5.3 The Graded Dose—Response Relationship and Therapeutic Response 50
- 5.4 Potency and Efficacy 51
- 5.5 Cellular Receptors and Drug Action 51
- 5.6 Types of Drug—Receptor Interactions 53
- 5.7 Pharmacology of the Future: Customizing Drug Therapy 53

Unit 2

Pharmacology and the Nurse–Patient Relationship 57

6 The Nursing Process in Pharmacology 58

- 6.1 Overview of the Nursing Process 59
- 6.2 Assessment of the Patient 60

- 6.3 Nursing Diagnoses 61
- 6.4 Planning: Establishing Goals and Outcomes 62
- 6.5 Implementing Specific Nursing Actions 63
 - PATIENT EDUCATION 63
- 6.6 Evaluating the Effects of Medications 64

7 Medication Errors and Risk Reduction 67

- 7.1 Defining Medication Errors 68
- 7.2 Factors Contributing to Medication Errors 68
- 7.3 The Impact of Medication Errors 68
- 7.4 Reporting and Documenting Medication Errors 70
 - DOCUMENTING IN THE PATIENT'S MEDICAL RECORD 71
 - REPORTING THE ERROR 71
 - SENTINEL AND PATIENT SAFETY EVENTS 71
- 7.5 Strategies for Reducing Medication Errors 71
- 7.6 Medication Reconciliation 72
- 7.7 Effective Patient Teaching for Medication Usage 73
- 7.8 How the Healthcare Industry Is Increasing Medication Safety 73

8 Drug Administration Throughout the Lifespan 77

- 8.1 Pharmacotherapy Across the Lifespan 78
- 8.2 Pharmacotherapy of the Pregnant Patient 78
 - PHYSIOLOGIC CHANGES DURING PREGNANCY THAT AFFECT PHARMACOTHERAPY 78
 - GESTATIONAL AGE AND DRUG THERAPY 79
 - PREGNANCY DRUG CATEGORIES 79
 - PREGNANCY REGISTRIES 80
- 8.3 Pharmacotherapy of the Lactating Patient 80
- 8.4 Pharmacotherapy of Infants 82
- 8.5 Pharmacotherapy of Toddlers 82
- 8.6 Pharmacotherapy of Preschoolers and School-Age Children 83
- 8.7 Pharmacotherapy of Adolescents 84
- 8.8 Pharmacotherapy of Young and Middle-Aged Adults 85
- 8.9 Pharmacotherapy of Older Adults 85

9 Individual Variations in Drug Response 89

- 9.1 The Concept of Holistic Pharmacotherapy 90
- 9.2 Psychosocial Influences on Pharmacotherapy 90
- 9.3 Cultural and Ethnic Influences on Pharmacotherapy 91
- 9.4 Community and Environmental Influences on Pharmacotherapy 92
- 9.5 Gender Influences on Pharmacotherapy 92
- 9.6 Genetic Influences on Pharmacotherapy 93

10 The Role of Complementary and Alternative Therapies in Pharmacology 97

- 10.1 Complementary and Alternative Medicine 98
- 10.2 Brief History of Herbal Therapies 99
- 10.3 Herbal Product Formulations 100
- 10.4 Regulation of Herbal Products and Dietary Supplements 101
- 10.5 The Pharmacologic Actions and Safety of Herbal Products 102
- 10.6 Specialty Supplements 103
- 10.7 Patient Teaching Regarding CAM 104

11 Emergency Preparedness and Poisonings 107

- 11.1 The Nature of Worldwide Epidemics and Bioterrorist Threats 108
- 11.2 Role of the Nurse in Emergency Preparedness 109
- 11.3 Strategic National Stockpile 110
- 11.4 Anthrax 111
- 11.5 Viruses 112
- 11.6 Toxic Chemicals 113
- 11.7 Ionizing Radiation 113
- 11.8 Management of Poisonings 114

Unit 3

The Nervous System 119

12 Cholinergic Drugs Affecting the Autonomic Nervous System 120

- 12.1 Overview of the Nervous System 121
- 12.2 Sympathetic and Parasympathetic Divisions 122
- 12.3 Structure and Function of Autonomic Synapses 123
- 12.4 Acetylcholine and Cholinergic Transmission 123
- 12.5 Classification and Naming of Drugs Affecting the Parasympathetic Nervous System 124
- 12.6 Clinical Applications of Cholinergic Drugs 126
- 12.7 Clinical Applications of Anticholinergics 127
 - Nursing Practice Application** Pharmacotherapy with Cholinergic Drugs 129
 - Nursing Practice Application** Pharmacotherapy with Anticholinergic Drugs 132

13 Adrenergic Drugs Affecting the Autonomic Nervous System 137

- 13.1 Norepinephrine and Adrenergic Transmission 138
- 13.2 Clinical Applications of Adrenergic Drugs 140
 - Nursing Practice Application** Pharmacotherapy with Adrenergic Drugs 143

- 13.3** Clinical Applications of Adrenergic-Blocking Drugs 144
Nursing Practice Application Pharmacotherapy with Adrenergic-Blocking Drugs 146
- 14** Drugs for Anxiety and Insomnia 151
- 14.1** Types of Anxiety Disorders 152
- 14.2** Specific Regions of the Brain Responsible for Anxiety and Wakefulness 152
- 14.3** Anxiety Management Through Pharmacologic and Nonpharmacologic Strategies 154
- 14.4** Insomnia and Its Link to Anxiety 154
- 14.5** Use of the Electroencephalogram to Diagnose Sleep Disorders 155
- 14.6** Treating Anxiety and Insomnia with CNS Drugs 156
- 14.7** Treating Anxiety and Insomnia with Benzodiazepines 156
- 14.8** Treating Anxiety with Antidepressants 158
- 14.9** Miscellaneous Anxiolytics for Anxiety and Sleep Disorders 160
- 14.10** Use of Barbiturates as Sedatives 161
Nursing Practice Application Pharmacotherapy for Anxiety or Sleep Disorders 163
- 15** Drugs for Seizures 168
- 15.1** Causes of Seizures 169
- 15.2** Types of Seizures 170
- 15.3** General Concepts of Antiseizure Pharmacotherapy 170
- 15.4** Mechanisms of Action of Antiseizure Drugs 172
- 15.5** Treating Seizures with Barbiturates 174
- 15.6** Treating Seizures with Benzodiazepines 176
- 15.7** Treating Seizures with Hydantoins and Related Drugs 176
- 15.8** Treating Seizures with Succinimides 179
Nursing Practice Application Pharmacotherapy with Antiseizure Drugs 180
- 16** Drugs for Emotional, Mood, and Behavioral Disorders 186
- 16.1** Characteristics and Forms of Depression 187
- 16.2** Assessment and Nonpharmacologic Treatment of Depression 187
- 16.3** Mechanism of Action of Antidepressants 188
- 16.4** Treating Depression with Selective Serotonin Reuptake Inhibitors 191
- 16.5** Treating Depression with Atypical Antidepressants 192
- 16.6** Treating Depression with Tricyclic Antidepressants 193
- 16.7** Treating Depression with MAOIs 194
- 16.8** Characteristics of Bipolar Disorder 195
- 16.9** Pharmacotherapy of Bipolar Disorder 195
- Nursing Practice Application** Pharmacotherapy for Mood Disorders 197
- 16.10** Characteristics of Attention-Deficit/Hyperactivity Disorder 199
- 16.11** Pharmacotherapy of ADHD 200
Nursing Practice Application Pharmacotherapy for Attention-Deficit/Hyperactivity Disorder 202
- 17** Drugs for Psychoses 208
- 17.1** The Nature of Psychoses 209
- 17.2** Schizophrenia 209
- 17.3** Pharmacologic Management of Psychoses 210
- 17.4** Treating Psychoses with Phenothiazines 211
- 17.5** Treating Psychoses with Nonphenothiazines 214
- 17.6** Treating Psychoses with Second-Generation (Atypical) Antipsychotics 215
Nursing Practice Application Pharmacotherapy with Antipsychotic Drugs 217
- 17.7** Treating Psychoses with Dopamine-Serotonin System Stabilizers 219
- 18** Drugs for the Control of Pain 223
- 18.1** Assessment and Classification of Pain 224
- 18.2** The Neural Mechanisms of Pain 224
- 18.3** Complementary and Alternative Therapies for Pain Management 226
- 18.4** Classification of Opioids 227
- 18.5** Pharmacotherapy with Opioid Agonists 227
- 18.6** Pharmacotherapy with Opioid Antagonists 230
 OPIOIDS WITH MIXED AGONIST-ANTAGONIST ACTIVITY 231
- 18.7** Treatment for Opioid Dependence 231
Nursing Practice Application Pharmacotherapy for Pain 232
- 18.8** Pharmacotherapy with NSAIDs 234
 ASPIRIN, IBUPROFEN, AND COX-2 INHIBITORS 234
 CENTRALLY ACTING DRUGS 234
- 18.9** Adjuvant Analgesics 236
- 18.10** Classification of Headaches 237
 DRUG THERAPY FOR TENSION HEADACHES 238
 ANTIMIGRAINE DRUGS 238
- 18.11** Drug Therapy for Migraines 238
Nursing Practice Application Pharmacotherapy for Migraines 240
- 19** Drugs for Local and General Anesthesia 245
- 19.1** Regional Loss of Sensation Using Local Anesthesia 246
 LOCAL ANESTHETICS 246
- 19.2** Mechanism of Action of Local Anesthetics 246
- 19.3** Classification of Local Anesthetics 248

- ESTERS 248
- AMIDES 248
- 19.4** Characteristics of General Anesthesia 250
 - GENERAL ANESTHETICS 250
- 19.5** Pharmacotherapy with Intravenous General Anesthetics 250
 - Nursing Practice Application** Pharmacotherapy with Local Anesthetics 251
- 19.6** Pharmacotherapy with Inhaled General Anesthetics 253
 - Nursing Practice Application** Pharmacotherapy with General Anesthetics 256
- 19.7** Drugs as Adjuncts to Surgery 257
 - NEUROMUSCULAR BLOCKERS 257
- 20** Drugs for Degenerative Diseases of the Nervous System 263
 - 20.1** Degenerative Diseases of the Central Nervous System 264
 - 20.2** Characteristics of Parkinson's Disease 264
 - 20.3** Treating Parkinson's Disease with Dopamine-Enhancing Drugs 266
 - 20.4** Treating Parkinson's Disease with Anticholinergic Drugs 269
 - 20.5** Characteristics of Alzheimer's Disease 270
 - 20.6** Treating Alzheimer's Disease with Cholinesterase Inhibitors 270
 - 20.7** Characteristics of Multiple Sclerosis 273
 - 20.8** Treating Multiple Sclerosis with Disease-Modifying Drugs 274
 - Nursing Practice Application** Pharmacotherapy for Neurodegenerative Diseases 275
- 21** Drugs for Neuromuscular Disorders 280
 - 21.1** Causes of Muscle Spasms 281
 - 21.2** Pharmacologic and Nonpharmacologic Strategies to Treat Muscle Spasms 281
 - 21.3** Centrally Acting Skeletal Muscle Relaxants Treat Muscle Spasms at the Brain and Spinal Cord Levels 281
 - 21.4** Causes and Treatment of Spasticity 283
 - 21.5** Direct-Acting Antispasmodics Treat Muscle Spasms Directly at the Muscle Tissue 284
 - 21.6** Neuromuscular Blockers Block the Effect of Acetylcholine at the Receptor 286
 - Nursing Practice Application** Pharmacotherapy for Muscle Spasms or Spasticity 287
- 22** Substance Abuse 292
 - 22.1** Overview of Substance Use Disorder 293
 - 22.2** Neurobiologic and Psychosocial Components of Substance Use Disorder 293

- 22.3** Physical and Psychologic Dependence 293
- 22.4** Withdrawal Syndrome 294
- 22.5** Tolerance 295
- 22.6** Central Nervous System Depressants 295
 - SEDATIVES AND SEDATIVE-HYPNOTICS 295
 - OPIOIDS 296
 - ETHYL ALCOHOL 296
- 22.7** Cannabinoids 298
 - MARIJUANA 298
- 22.8** Hallucinogens 298
 - LSA 298
 - RECREATIONAL AND CLUB DRUGS 299
- 22.9** Central Nervous System Stimulants 299
 - AMPHETAMINES AND METHYLPHENIDATE 299
 - COCAINE 300
 - CAFFEINE 300
- 22.10** Nicotine 300
 - TOBACCO USE AND NICOTINE PRODUCTS 300
- 22.11** The Nurse's Role in Substance Use 301

Unit 4

The Cardiovascular and Urinary Systems 305

- 23** Drugs for Lipid Disorders 306
 - 23.1** Types of Lipids 307
 - 23.2** Lipoproteins 307
 - 23.3** LDL and Cardiovascular Disease 308
 - 23.4** Controlling Lipid Levels Through Lifestyle Changes 309
 - 23.5** Pharmacotherapy with Statins 310
 - 23.6** Bile Acid Sequestrants for Reducing Cholesterol and LDL Levels 313
 - 23.7** Pharmacotherapy with Niacin 314
 - 23.8** Pharmacotherapy with Fibrin Acid Drugs 315
 - 23.9** Pharmacotherapy with Miscellaneous Drugs for Dyslipidemias 316
 - Nursing Practice Application** Lipid-Lowering Pharmacotherapy 316
- 24** Diuretic Therapy and Drugs for Kidney Failure 321
 - 24.1** Functions of the Kidneys 322
 - 24.2** Renal Reabsorption and Secretion 322
 - 24.3** Diagnosis and Pharmacotherapy of Kidney Failure 323
 - 24.4** Mechanisms of Action of Diuretics 324
 - 24.5** Pharmacotherapy with Loop Diuretics 325
 - 24.6** Pharmacotherapy with Thiazide Diuretics 327
 - 24.7** Pharmacotherapy with Potassium-Sparing Diuretics 329

- 24.8** Miscellaneous Diuretics for Specific Indications 330
Nursing Practice Application Pharmacotherapy with Diuretics 331
- 25** Drugs for Fluid Balance, Electrolyte, and Acid–Base Disorders 336
- 25.1** Body Fluid Compartments 337
- 25.2** Osmolality, Tonicity, and the Movement of Body Fluids 337
- 25.3** Regulation of Fluid Intake and Output 338
- 25.4** Intravenous Therapy with Crystalloids and Colloids 338
 CRYSTALLOIDS 338
 COLLOIDS 339
- 25.5** Physiologic Role of Electrolytes 340
- 25.6** Pharmacotherapy of Sodium Imbalances 341
 HYPERNATREMIA 341
 HYPONATREMIA 342
- 25.7** Pharmacotherapy of Potassium Imbalances 342
 HYPERKALEMIA 342
 HYPOKALEMIA 343
- 25.8** Buffers and the Maintenance of Body PH 344
Nursing Practice Application Intravenous Fluid and Electrolyte Replacement Therapy 345
- 25.9** Pharmacotherapy of Acidosis 347
- 25.10** Pharmacotherapy of Alkalosis 348
- 26** Drugs for Hypertension 351
- 26.1** Factors Responsible for Blood Pressure 352
- 26.2** Physiologic Regulation of Blood Pressure 353
- 26.3** Etiology and Pathogenesis of Hypertension 353
- 26.4** Nonpharmacologic Management of Hypertension 355
- 26.5** Guidelines for the Management of Hypertension 355
- 26.6** Treating Hypertension with Diuretics 358
- 26.7** Treating Hypertension with Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers 359
- 26.8** Treating Hypertension with Calcium Channel Blockers 361
- 26.9** Treating Hypertension with Adrenergic Antagonists 363
 BETA-ADRENERGIC BLOCKERS 363
 ALPHA₁-ADRENERGIC BLOCKERS 364
 ALPHA₂-ADRENERGIC AGONISTS 364
- 26.10** Treating Hypertension with Direct Vasodilators 365
Nursing Practice Application Pharmacotherapy for Hypertension 367
- 27** Drugs for Heart Failure 372
- 27.1** The Etiology and Pathogenesis of Heart Failure 373
- 27.2** Treatment of Heart Failure with Angiotensin-Converting Inhibitors and Angiotensin Receptor Blockers 375
- 27.3** Treatment of Heart Failure with Diuretics 377
- 27.4** Treatment of Heart Failure with Beta-Adrenergic Blockers (Antagonists) 378
- 27.5** Treatment of Heart Failure with Cardiac Glycosides 378
- 27.6** Treatment of Heart Failure with Vasodilators 380
- 27.7** Treatment of Heart Failure with Phosphodiesterase Inhibitors 381
Nursing Practice Application Pharmacotherapy for Heart Failure 382
- 28** Drugs for Angina Pectoris and Myocardial Infarction 387
- 28.1** Pathogenesis of Coronary Artery Disease 388
- 28.2** Pathogenesis of Angina Pectoris 388
- 28.3** Nonpharmacologic Management of Angina 389
- 28.4** Treating Angina with Organic Nitrates 390
- 28.5** Treating Angina with Beta-Adrenergic Blockers 392
- 28.6** Treating Angina with Calcium Channel Blockers 392
Nursing Practice Application Pharmacotherapy with Organic Nitrates 393
- 28.7** Diagnosis of Acute Coronary Syndrome 396
- 28.8** Treating Myocardial Infarction with Thrombolytics 397
- 28.9** Adjunct Drugs for Symptoms and Complications of Acute Myocardial Infarction 399
 ANTIPLATELET AND ANTICOAGULANT DRUGS 399
 NITRATES 400
 BETA-ADRENERGIC BLOCKERS 400
 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 400
 PAIN MANAGEMENT 400
- 29** Drugs for Shock 404
- 29.1** Characteristics of Shock 405
- 29.2** Causes of Shock 405
- 29.3** Treatment Priorities for a Patient in Shock 406
- 29.4** Treating Shock with Intravenous Fluid Therapy 407
- 29.5** Treating Shock with Vasoconstrictors (Vasopressors) 407
- 29.6** Treating Shock with Inotropic Drugs 409
Nursing Practice Application Pharmacotherapy for Shock 410
- 29.7** Pharmacotherapy of Anaphylaxis 412
- 30** Drugs for Dysrhythmias 416
- 30.1** Etiology and Classification of Dysrhythmias 417
- 30.2** Conduction Pathways in the Myocardium 417
- 30.3** The Electrocardiograph 418

- 30.4 Nonpharmacologic Treatment of Dysrhythmias 419
- 30.5 Phases of the Myocardial Action Potential 419
- 30.6 Mechanisms and Classification of Antidysrhythmic Drugs 421
- 30.7 Treating Dysrhythmias with Sodium Channel Blockers 421
- 30.8 Treating Dysrhythmias with Beta-Adrenergic Antagonists 421
- 30.9 Treating Dysrhythmias with Potassium Channel Blockers 423
- 30.10 Treating Dysrhythmias with Calcium Channel Blockers 425
- 30.11 Miscellaneous Drugs for Dysrhythmias 427
 - Nursing Practice Application** Pharmacotherapy with Antidysrhythmic Drugs 427

31 Drugs for Coagulation Disorders 431

- 31.1 The Process of Hemostasis 432
- 31.2 Removal of Blood Clots 433
- 31.3 Alterations of Hemostasis 434
 - THROMBOEMBOLIC DISORDERS 434
 - COAGULATION DISORDERS 434
- 31.4 Mechanisms of Coagulation Modification 434
- 31.5 Pharmacotherapy with Anticoagulants 437
 - HEPARIN, LOW-MOLECULAR-WEIGHT HEPARINS, AND RELATED DRUGS 437
 - VITAMIN K ANTAGONISTS 437
 - DIRECT THROMBIN INHIBITORS 437
 - FACTOR XA INHIBITORS 439
- 31.6 Pharmacotherapy with Antiplatelet Drugs 440
 - Nursing Practice Application** Pharmacotherapy with Anticoagulant and Antiplatelet Drugs 441
- 31.7 Pharmacotherapy with Thrombolytics 443
 - Nursing Practice Application** Pharmacotherapy with Thrombolytics 444
- 31.8 Pharmacotherapy with Hemostatics 446
- 31.9 Pharmacotherapy of Hemophilia 447

32 Drugs for Hematopoietic Disorders 451

- 32.1 Hematopoiesis 452
- 32.2 Pharmacotherapy with Erythropoiesis-Stimulating Drugs 454
- 32.3 Pharmacotherapy with Colony-Stimulating Factors 454
 - Nursing Practice Application** Pharmacotherapy with Erythropoiesis-Stimulating Drugs 455
 - Nursing Practice Application** Pharmacotherapy with Colony-Stimulating Factors 457
- 32.4 Pharmacotherapy with Platelet Enhancers 459
- 32.5 Classification of Anemias 460
- 32.6 Pharmacotherapy with Vitamin B₁₂ and Folic Acid 460

- 32.7 Pharmacotherapy with Iron 461
 - Nursing Practice Application** Pharmacotherapy for Anemia (Folic Acid, Vitamin B₁₂, Ferrous Sulfate) 464

Unit 5

The Immune System 469

33 Drugs for Inflammation and Fever 470

- 33.1 The Function of Inflammation 471
- 33.2 The Role of Chemical Mediators in Inflammation 471
- 33.3 General Strategies for Treating Inflammation 472
- 33.4 Treating Inflammation with NSAIDs 473
 - SALICYLATES 474
 - IBUPROFEN AND IBUPROFEN-LIKE NSAIDS 475
 - SELECTIVE COX-2 INHIBITORS 475
- 33.5 Treating Acute or Severe Inflammation with Corticosteroids 476
- 33.6 Treating Fever with Antipyretics 478
 - Nursing Practice Application** Pharmacotherapy with Anti-Inflammatory and Antipyretic Drugs 479

34 Drugs for Immune System Modulation 485

- 34.1 Innate (Nonspecific) Body Defenses and the Immune Response 486
- 34.2 Humoral Immune Response and Antibodies 486
- 34.3 Administration of Vaccines 487
- 34.4 Cell-Mediated Immunity and Cytokines 490
- 34.5 Pharmacotherapy with Biologic Response Modifiers 491
 - Nursing Practice Application** Pharmacotherapy with Immunostimulants 495
- 34.6 Immunosuppressants for Preventing Transplant Rejection and for Treating Inflammation 496
 - TRANSPLANTATION 496
 - ACUTE INFLAMMATORY DISORDERS 497
 - Nursing Practice Application** Pharmacotherapy with Immunosuppressants 499

35 Drugs for Bacterial Infections 503

- 35.1 Pathogenicity and Virulence 504
- 35.2 Describing and Classifying Bacteria 504
- 35.3 Classification of Anti-Infective Drugs 505
- 35.4 Actions of Anti-Infective Drugs 505
- 35.5 Acquired Resistance 506
- 35.6 Selection of an Effective Antibiotic 508
- 35.7 Host Factors 509
 - HOST DEFENSES 509
 - LOCAL TISSUE CONDITIONS 509

- ALLERGY HISTORY 509
OTHER PATIENT VARIABLES 509
- 35.8 Pharmacotherapy with Penicillins 510
35.9 Pharmacotherapy with Cephalosporins 512
35.10 Pharmacotherapy with Tetracyclines 514
35.11 Pharmacotherapy with Macrolides 514
35.12 Pharmacotherapy with Aminoglycosides 516
35.13 Pharmacotherapy with Fluoroquinolones 518
35.14 Pharmacotherapy with Sulfonamides and Urinary Antiseptics 519
35.15 Pharmacotherapy with Carbapenems and Miscellaneous Antibacterials 521
Nursing Practice Application Pharmacotherapy with Antibacterial Drugs 524
- 36 Drugs for Tubercular, Fungal, Protozoan, and Helminthic Infections 530**
- 36.1 Pharmacotherapy of Tuberculosis 532
36.2 Characteristics of Fungi 532
Nursing Practice Application Pharmacotherapy with Antitubercular Drugs 533
36.3 Classification of Mycoses 535
36.4 Mechanism of Action of Antifungal Drugs 536
36.5 Pharmacotherapy of Systemic Fungal Diseases 536
36.6 Pharmacotherapy with the Azole Antifungals 537
SYSTEMIC AZOLES 539
TOPICAL AZOLES 539
36.7 Pharmacotherapy of Superficial Fungal Infections 539
Nursing Practice Application Pharmacotherapy with Antifungal Drugs 541
36.8 Pharmacotherapy of Malaria 543
36.9 Pharmacotherapy of Nonmalarial Protozoan Infections 544
36.10 Pharmacotherapy of Helminthic Infections 546
- 37 Drugs for Viral Infections 551**
- 37.1 Characteristics of Viruses 552
37.2 Replication of HIV 553
37.3 General Principles of HIV Pharmacotherapy 554
37.4 Classification of Drugs for HIV and AIDS 555
37.5 Pharmacotherapy with Reverse Transcriptase Inhibitors 557
37.6 Pharmacotherapy with Protease Inhibitors 558
37.7 Pharmacotherapy with Integrase Strand Inhibitors and Entry Inhibitors 559
Nursing Practice Application Pharmacotherapy for HIV and AIDS 561
37.8 Prevention of Perinatal Transmission of HIV 563
37.9 Postexposure Prophylaxis of HIV Infection Following Occupational Exposure 564
37.10 Pharmacotherapy of Herpesvirus Infections 565
37.11 Pharmacotherapy of Influenza 566
37.12 Pharmacotherapy of Viral Hepatitis 567
HEPATITIS A 567
HEPATITIS B 567
HEPATITIS C AND OTHER HEPATITIS VIRUSES 568
Nursing Practice Application Pharmacotherapy for Non-HIV Viral Infections 569
- 38 Drugs for Neoplasia 574**
- 38.1 Characteristics of Cancer 575
38.2 Causes of Cancer 575
38.3 Goals of Cancer Chemotherapy: Cure, Control, and Palliation 576
38.4 Growth Fraction and Success of Chemotherapy 577
38.5 Achieving a Total Cancer Cure 578
38.6 Special Chemotherapy Protocols and Strategies 578
COMBINATION CHEMOTHERAPY 578
DOSING SCHEDULES 579
38.7 Toxicity of Antineoplastic Drugs 579
38.8 Pharmacotherapy with Alkylating Agents 580
38.9 Pharmacotherapy with Antimetabolites 581
FOLIC ACID ANALOGS 581
PURINE AND PYRIMIDINE ANALOGS 583
38.10 Pharmacotherapy with Antitumor Antibiotics 583
38.11 Pharmacotherapy with Natural Products 585
38.12 Pharmacotherapy with Hormones and Hormone Antagonists 585
CORTICOSTEROIDS (GLUCOCORTICOID) 587
GONADAL HORMONES 587
ESTROGEN ANTAGONISTS (ANTIESTROGENS) 587
ANDROGEN ANTAGONISTS (ANTIANDROGENS) 588
38.13 Pharmacotherapy with Biologic Response Modifiers and Targeted Therapies 591
38.14 Miscellaneous Antineoplastics 591
Nursing Practice Application Pharmacotherapy for Cancer 594

Unit 6

The Respiratory System 599

39 Drugs for Allergic Rhinitis and the Common Cold 600

- 39.1 Physiology of the Upper Respiratory Tract 601
39.2 Pharmacotherapy of Allergic Rhinitis 602
39.3 Pharmacology of Allergic Rhinitis with H₁-Receptor Antagonists and Mast Cell Stabilizers 603
39.4 Pharmacotherapy of Allergic Rhinitis with Intranasal Corticosteroids 605
39.5 Pharmacotherapy of Nasal Congestion with Decongestants 606
COMMON COLD 608

- 39.6 Pharmacotherapy with Antitussives 608
- 39.7 Pharmacotherapy with Expectorants, Mucolytics, and Drugs for Cystic Fibrosis 609
- Nursing Practice Application** Pharmacotherapy for Symptomatic Cold Relief 611

40 Drugs for Asthma and Other Pulmonary Disorders 616

- 40.1 Physiology of the Lower Respiratory Tract 617
- 40.2 Bronchiolar Smooth Muscle 617
- 40.3 Administration of Pulmonary Drugs via Inhalation 618
- 40.4 Pathophysiology of Asthma 618
- 40.5 Treating Acute Asthma with Beta-Adrenergic Agonists 620
- 40.6 Treating Chronic Asthma with Anticholinergics 623
- 40.7 Treating Chronic Asthma with Methylxanthines 624
- 40.8 Prophylaxis of Asthma with Corticosteroids 624
- 40.9 Prophylaxis of Asthma with Leukotriene Modifiers 626
- 40.10 Prophylaxis of Asthma with Mast Cell Stabilizers 626
- 40.11 Monoclonal Antibodies for Asthma Prophylaxis 627
- 40.12 Pharmacotherapy of COPD 627
- Nursing Practice Application** Pharmacotherapy for Asthma and COPD 628

Unit 7

The Gastrointestinal System 633

41 Drugs for Peptic Ulcer Disease 634

- 41.1 Normal Digestive Processes 635
- 41.2 Acid Production by the Stomach 636
- 41.3 Pathogenesis of Peptic Ulcer Disease 636
- 41.4 Pathogenesis of Gastroesophageal Reflux Disease 637
- 41.5 Pharmacotherapy with Proton Pump Inhibitors 638
- 41.6 Pharmacotherapy with H₂-Receptor Antagonists 639
- 41.7 Pharmacotherapy with Antacids 641
- 41.8 Pharmacotherapy of *H. Pylori* Infection 643
- Nursing Practice Application** Pharmacotherapy for Peptic Ulcer and Gastroesophageal Reflux Diseases 643

- 41.9 Miscellaneous Drugs for Peptic Ulcer Disease 645

42 Drugs for Bowel Disorders and Other Gastrointestinal Conditions 649

- 42.1 Normal Function of the Lower Digestive Tract 650
- 42.2 Pathophysiology of Constipation 651
- 42.3 Pharmacotherapy with Laxatives 651
- 42.4 Pathophysiology of Diarrhea 653
- 42.5 Pharmacotherapy with Antidiarrheals 654

- 42.6 Pharmacotherapy of Irritable Bowel Syndrome 655
- 42.7 Pharmacotherapy of Inflammatory Bowel Disease 657

Nursing Practice Application Pharmacotherapy for Bowel Disorders 658

- 42.8 Pathophysiology of Nausea and Vomiting 660

- 42.9 Pharmacotherapy with Antiemetics 660

SEROTONIN (5-HT₃) ANTAGONISTS 662

ANTIHISTAMINES AND ANTICHOLINERGICS 662

PHENOTHIAZINE AND PHENOTHIAZINE-LIKE DRUGS 662

CORTICOSTEROIDS 662

OTHER ANTIEMETICS 662

EMETICS 663

Nursing Practice Application Pharmacotherapy with Antiemetic Drugs 663

- 42.10 Pharmacotherapy of Pancreatitis 665

43 Drugs for Nutritional Disorders 668

- 43.1 Role of Vitamins in Maintaining Health 669

- 43.2 Classification of Vitamins 669

- 43.3 Recommended Dietary Allowances 669

- 43.4 Indications for Vitamin Pharmacotherapy 669

- 43.5 Pharmacotherapy with Lipid-Soluble Vitamins 671

- 43.6 Pharmacotherapy with Water-Soluble Vitamins 672

- 43.7 Indications for Mineral Pharmacotherapy 674

- 43.8 Pharmacotherapy with Minerals 676

Nursing Practice Application Pharmacotherapy with Vitamins and Minerals 678

- 43.9 Etiology of Undernutrition 679

- 43.10 Enteral Nutrition 680

- 43.11 Parenteral Nutrition 680

Nursing Practice Application Enteral and Parenteral Nutrition Therapy 681

- 43.12 Etiology of Obesity 683

- 43.13 Pharmacotherapy of Obesity 684

Unit 8

The Endocrine System 689

44 Drugs for Pituitary, Thyroid, and Adrenal Disorders 690

- 44.1 The Endocrine System and Homeostasis 691

- 44.2 Indications for Hormone Pharmacotherapy 691

- 44.3 The Endocrine Structures of the Brain 692

- 44.4 Pharmacotherapy with Hypothalamic and Pituitary Hormones 693

GROWTH HORMONE 694

ANTIDIURETIC HORMONE 695

Nursing Practice Application Pharmacotherapy with Hypothalamic and Pituitary Hormones 696

- 44.5 Normal Function of the Thyroid Gland 697
- 44.6 Pharmacotherapy of Hypothyroidism 698
- 44.7 Pharmacotherapy of Hyperthyroidism 699
- Nursing Practice Application** Pharmacotherapy for Thyroid Disorders 701
- 44.8 Normal Function of the Adrenal Glands 703
- GONADOCORTICOIDS 703
- MINERALOCORTICOIDS 703
- GLUCOCORTICOIDS 703
- 44.9 Regulation of Corticosteroid Secretion 703
- 44.10 Pharmacotherapy with Corticosteroids 704
- 44.11 Pharmacotherapy of Cushing's Syndrome 706
- Nursing Practice Application** Pharmacotherapy with Systemic Corticosteroids 708
- 45 Drugs for Diabetes Mellitus 712**
- 45.1 Regulation of Blood Glucose Levels 713
- 45.2 Etiology and Characteristics of Type 1 Diabetes Mellitus 713
- 45.3 Pharmacotherapy for Type 1 Diabetes Mellitus 715
- INSULIN ADJUNCT 717
- Nursing Practice Application** Pharmacotherapy with Insulin 718
- 45.4 Etiology and Characteristics of Type 2 Diabetes Mellitus 720
- 45.5 Pharmacotherapy for Type 2 Diabetes Mellitus 721
- SULFONYLUREAS 721
- BIGUANIDES 723
- ALPHA-GLUCOSIDASE INHIBITORS 723
- THIAZOLIDINEDIONES 723
- MEGLITINIDES 723
- INCRETIN THERAPIES AND MISCELLANEOUS DRUGS 723
- Nursing Practice Application** Pharmacotherapy for Type 2 Diabetes 725
- 46 Drugs for Disorders and Conditions of the Female Reproductive System 729**
- 46.1 Hypothalamic and Pituitary Regulation of Female Reproductive Function 730
- 46.2 Ovarian Control of Female Reproductive Function 730
- 46.3 Estrogens and Progestins as Oral Contraceptives 731
- Nursing Practice Application** Pharmacotherapy with Hormonal Contraceptives 736
- 46.4 Drugs for Emergency Contraception and Termination of Early Pregnancy 737
- 46.5 Hormone Replacement Therapy 739
- 46.6 Pharmacotherapy with Progestins 741
- 46.7 Pharmacologic Management of Uterine Contractions 742
- Nursing Practice Application** Pharmacotherapy with Oxytocin 745

- 46.8 Pharmacotherapy of Female Fertility 747
- 46.9 Pharmacotherapy of Female Hypoactive Sexual Desire Disorder 748

47 Drugs for Disorders and Conditions of the Male Reproductive System 751

- 47.1 Hypothalamic and Pituitary Regulation of Male Reproductive Function 752
- 47.2 Pharmacotherapy with Androgens 752
- Nursing Practice Application** Pharmacotherapy with Androgens 755
- 47.3 Pharmacotherapy of Male Infertility 756
- 47.4 Pharmacotherapy of Erectile Dysfunction 757
- 47.5 Pharmacotherapy of Benign Prostatic Hyperplasia 759
- Nursing Practice Application** Pharmacotherapy for Benign Prostatic Hyperplasia 762

Unit 9

The Integumentary System, Eyes, and Ears 767

48 Drugs for Bone and Joint Disorders 768

- 48.1 Role of Calcium and Vitamin D in Bone Homeostasis 769
- 48.2 Pharmacotherapy of Hypocalcemia 771
- 48.3 Pathophysiology of Metabolic Bone Diseases 771
- 48.4 Pharmacotherapy of Metabolic Bone Diseases 774
- VITAMIN D THERAPY 774
- BISPHOSPHONATES 774
- SELECTIVE ESTROGEN RECEPTOR MODULATORS 776
- OTHER DRUGS FOR METABOLIC BONE DISEASE 777
- Nursing Practice Application** Pharmacotherapy for Osteoporosis 778
- 48.5 Pharmacotherapy of Osteoarthritis 779
- 48.6 Pharmacotherapy of Rheumatoid Arthritis 781
- 48.7 Pharmacotherapy of Gout and Hyperuricemia 782
- Nursing Practice Application** Pharmacotherapy for Rheumatoid Arthritis and Osteoarthritis 783
- TREATMENT OF ACUTE GOUT 785
- TREATMENT OF CHRONIC GOUT AND PROPHYLAXIS 786
- Nursing Practice Application** Pharmacotherapy for Gout 787

49 Drugs for Skin Disorders 792

- 49.1 Structure and Function of the Skin 793
- EPIDERMIS 793
- DERMIS 794
- SUBCUTANEOUS TISSUE 794

- 49.2 Classification of Skin Disorders 794
- 49.3 Pharmacotherapy of Bacterial, Fungal, and Viral Skin Infections 795
- 49.4 Pharmacotherapy with Scabicides and Pediculicides 796
 - Nursing Practice Application** Pharmacotherapy for Lice or Mite Infestation 797
- 49.5 Pharmacotherapy of Acne 798
- 49.6 Pharmacotherapy of Rosacea 799
 - Nursing Practice Application** Pharmacotherapy for Acne and Related Skin Conditions 801
- 49.7 Pharmacotherapy of Dermatitis 802
- 49.8 Pharmacotherapy of Psoriasis 804
 - TOPICAL THERAPIES 804
 - SYSTEMIC THERAPIES 805
 - NONPHARMACOLOGIC THERAPIES 805
- 49.9 Pharmacotherapy of Sunburn and Minor Skin Irritation 807

- 50 Drugs for Eye and Ear Disorders 810**
 - 50.1 Anatomy of the Eye 811
 - 50.2 Types of Glaucoma 812
 - 50.3 General Principles of Glaucoma Pharmacotherapy 813
 - 50.4 Pharmacotherapy of Glaucoma 813
 - PROSTAGLANDIN ANALOGS 813
 - AUTONOMIC DRUGS 815
 - CARBONIC ANHYDRASE INHIBITORS AND MISCELLANEOUS DRUGS 816
 - OSMOTIC DIURETICS 816
 - 50.5 Pharmacotherapy for Eye Exams and Minor Eye Conditions 816
 - Nursing Practice Application** Pharmacotherapy for Glaucoma 817
 - 50.6 Pharmacotherapy with Otic Medications 819

- Appendix A** Answers 823
- Appendix B** Institute for Safe Medication Practices (ISMP): ISMP List of *Error-Prone Abbreviations, Symbols, and Dose Designations* 881
- Appendix C** Institute for Safe Medication Practices (ISMP) List of High-Alert Medications in Acute Care Settings 884
- Appendix D** Calculating Dosages 885
- Index 887
- Special Features 929

